Central retinal thickness was lower 28 weeks after switching to aflibercept.
Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) study.
L Tiosano … M Goldstein
Eye (London, England) · Jun 2017 · Q1 in Ophthalmology
Purpose
The purpose of this study is to evaluate an early switch to aflibecept in eyes with neovascular age-related macular degeneration (nvAMD) showing partial or lack of response for initial therapy with bevacizumab.
Methods
The Aflibercept as a Second Line Therapy for Neovascular Age Related Macular Degeneration in Israel (ASLI) was a prospective, multicenter, single-arm clinical trial.
n = 46 patients
277±70 microns
Results
277±70 microns
lower thickness in the eye’s central retina after 28 weeks
n = 46 patients
More results
The mean number of prior bevacizumab injections was 5.5±2.9.
The mean visual acuity improved from 60.3±10 ETDRS letters at baseline to 63.1±15 letters at week 28 (P=0.02, paired t-test).
Twenty-two eyes had three to five prior bevacizumab injections (mean 5.1±0.7), and 25 eyes had six to nine prior injections (7.32±1.2).
More results
Both groups had reduced central subfield thickness from baseline to week 28 (P=0.0004 and P=0.0007; paired t-test, respectively).
“
Conclusion
The ASLI study demonstrated improved BCVA and reduced central subfield thickness following an early switch to aflibercept therapy in eyes with prior incomplete response to initial therapy with three to nine bevacizumab injections.
